For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged. But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.

Pharma and the Covid19 Crisis – An Interaction with Sunil Attavar, CMD, Group Pharma

This is the first part of MedicinMan interview series...

Has Indian Pharma Seen The Longevity Tsunami Coming?

Why India Must Urgently Reinvent Healthcare for a 100-Year...

Indian Pharma’s November 2025: How GLP-1s Rewired the Market

Indian pharma wrapped up November 2025 with serious velocity....

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Marketing

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Policies/Sales

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Strategy

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Digital Marketing Kick Starter for Pharma Marketers

An interview with Salil Kallianpur - Executive VP at GSK Primary Care on the state of digital in pharma marketing and pointers for digital marketing success.

Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion

Novo Nordisk has announced plans to acquire Akero Therapeutics...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Is Pharma’s Business Model like McDonald’s? ...

Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation? McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management. More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology. Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells. While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.